Chalcone-Coumarin Derivatives as Potential Anti-Cancer Drugs: An in vitro and in vivo Investigation
- Authors: Jamier V.1, Marut W.2, Valente S.3, Chereau C.4, Chouzenoux S.5, Nicco C.6, Lemarechal H.7, Weill B.8, Kirsch G.9, Jacob C.10, Batteux F.11
-
Affiliations:
- aff1
- aff2
- aff3
- aff4
- aff5
- aff6
- aff7
- aff8
- aff9
- aff10
- aff11
- Issue: Vol 14, No 7 (2014)
- Pages: 963-974
- Section: Oncology
- URL: https://genescells.com/1871-5206/article/view/695115
- DOI: https://doi.org/10.2174/1871520613666131224124445
- ID: 695115
Cite item
Full Text
Abstract
Cancer cells display an overproduction of reactive oxygen species resulting from an exaggerated intrinsic oxidative stress. However, the concept of deleterious oxidants versus beneficial antioxidants has recently evolved. Indeed, molecules like natural coumarins have shown anti-oxidant or pro-oxidant properties depending on their intracellular concentration. Therefore, we have investigated the structure-activity relationship of a variety of coumarin derivatives in terms of cytotoxicity towards human and murine carcinoma cell lines (HT29, HepG2, A549, MCF7, OVCAR and CT26). Amongst those compounds, (E)-7-methoxy-4-(3-oxo-3- phenylprop-1-enyl)-2H-chromen-2-one and (E)-7-hydroxy-4-(3-(4-hydroxyphenyl)-3-oxoprop-1-enyl)-2H-chromen-2-one displayed the most potent cytotoxic effect on colon cancer cells, CT26, (IC50=4.9µM) linked to their pro-oxidant properties. Those compounds triggered the in vitro production of reactive oxygen species by tumor cells, leading to their death through a necrotic process. In vivo, molecules also slowed down tumor growth by 65.7% and 35.4%, respectively, without inducing significant side effects.
About the authors
Vincent Jamier
aff1
Email: info@benthamscience.net
Wioleta Marut
aff2
Email: info@benthamscience.net
Sergio Valente
aff3
Email: info@benthamscience.net
Christiane Chereau
aff4
Email: info@benthamscience.net
Sandrine Chouzenoux
aff5
Email: info@benthamscience.net
Carole Nicco
aff6
Email: info@benthamscience.net
Herve Lemarechal
aff7
Email: info@benthamscience.net
Bernard Weill
aff8
Email: info@benthamscience.net
Gilbert Kirsch
aff9
Email: info@benthamscience.net
Claus Jacob
aff10
Email: info@benthamscience.net
Frederic Batteux
aff11
Email: info@benthamscience.net
Supplementary files
